Ayse Oner1, Zeynep Burcin Gonen2,3, Duygu Gülmez Sevim4, Neslihan Sinim Kahraman5, Metin Unlu6. 1. Department of Ophthalmology, Faculty of Medicine, Erciyes University, 38039, Kayseri, Turkey. aoner@erciyes.edu.tr. 2. Genome and Stem Cell Center (GENKOK), Erciyes University, Kayseri, Turkey. 3. Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Erciyes University, Kayseri, Turkey. 4. Department of Ophthalmology, Erciyes University, Kayseri, Turkey. 5. Kayseri Acibadem Hospital, Kayseri, Turkey. 6. Department of Ophthalmology, Faculty of Medicine, Erciyes University, 38039, Kayseri, Turkey.
Abstract
PURPOSE: This prospective clinical case series aimed to investigate the safety and efficacy of suprachoroidal adipose tissue-derived mesenchymal stem cell (ADMSC) implantation in patients with optic nerve diseases. METHODS: This prospective, single-center, phase 1/2 study enrolled 4 eyes of 4 patients with optic atrophy of various reasons who underwent suprachoroidal implantation of ADMSCs. The best-corrected visual acuity (BCVA) in the study was HM at 1 m. The worse eye of the patient was operated. Patients were evaluated on the first day, first week, first month, third and sixth months postoperatively. BCVA, anterior segment and fundus examination, color photography, optical coherence tomography (OCT) and visual field examination were carried out at each visit. Fundus fluorescein angiography and multifocal electroretinography (mfERG) recordings were performed at the end of the first, third and sixth months and anytime if necessary during the follow-up. RESULTS: All 4 patients completed the six-month follow-up. None of them had any systemic or ocular complications. All of the patients experienced visual acuity improvement, visual field improvement and improvement in the mfERG recordings. We found choroidal thickening in OCT of the 4 patients. CONCLUSION: Even though the sample size is small, the improvements were still encouraging. Stem cell treatment with suprachoroidal implantation of ADMSCs seems to be safe and effective in the treatment for optic nerve diseases that currently have no curative treatment options.
PURPOSE: This prospective clinical case series aimed to investigate the safety and efficacy of suprachoroidal adipose tissue-derived mesenchymal stem cell (ADMSC) implantation in patients with optic nerve diseases. METHODS: This prospective, single-center, phase 1/2 study enrolled 4 eyes of 4 patients with optic atrophy of various reasons who underwent suprachoroidal implantation of ADMSCs. The best-corrected visual acuity (BCVA) in the study was HM at 1 m. The worse eye of the patient was operated. Patients were evaluated on the first day, first week, first month, third and sixth months postoperatively. BCVA, anterior segment and fundus examination, color photography, optical coherence tomography (OCT) and visual field examination were carried out at each visit. Fundus fluorescein angiography and multifocal electroretinography (mfERG) recordings were performed at the end of the first, third and sixth months and anytime if necessary during the follow-up. RESULTS: All 4 patients completed the six-month follow-up. None of them had any systemic or ocular complications. All of the patients experienced visual acuity improvement, visual field improvement and improvement in the mfERG recordings. We found choroidal thickening in OCT of the 4 patients. CONCLUSION: Even though the sample size is small, the improvements were still encouraging. Stem cell treatment with suprachoroidal implantation of ADMSCs seems to be safe and effective in the treatment for optic nerve diseases that currently have no curative treatment options.
Authors: Donald C Hood; Michael Bach; Mitchell Brigell; David Keating; Mineo Kondo; Jonathan S Lyons; Michael F Marmor; Daphne L McCulloch; Anja M Palmowski-Wolfe Journal: Doc Ophthalmol Date: 2011-10-30 Impact factor: 2.379
Authors: Paolo Giuseppe Limoli; Enzo Maria Vingolo; Marco Ulisses Morales; Marcella Nebbioso; Celeste Limoli Journal: Medicine (Baltimore) Date: 2014-12 Impact factor: 1.889
Authors: Louise A Mesentier-Louro; Camila Zaverucha-do-Valle; Paulo H Rosado-de-Castro; Almir J Silva-Junior; Pedro M Pimentel-Coelho; Rosalia Mendez-Otero; Marcelo F Santiago Journal: Stem Cells Int Date: 2015-11-16 Impact factor: 5.443
Authors: Sara J Coulon; Joel S Schuman; Yiqin Du; Mohammad Reza Bahrani Fard; C Ross Ethier; W Daniel Stamer Journal: Prog Retin Eye Res Date: 2022-04-06 Impact factor: 19.704